These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37033966)

  • 1. Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy.
    Liu Z; Wan R; Bai H; Wang J
    Front Immunol; 2023; 14():1104560. PubMed ID: 37033966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.
    Xu M; Lu JH; Zhong YZ; Jiang J; Shen YZ; Su JY; Lin SY
    Front Oncol; 2022; 12():870914. PubMed ID: 35444934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy.
    Torricelli F; Donati B; Reggiani F; Manicardi V; Piana S; Valli R; Lococo F; Ciarrocchi A
    Mol Cancer; 2023 Jul; 22(1):114. PubMed ID: 37460925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
    Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for immunotherapy in malignant pleural mesothelioma?
    Tartarone A; Lerose R; Aieta M
    Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
    Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
    Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
    Zhang C; Kang Y; Ma R; Chen F; Chen F; Dong X
    J Cancer Res Ther; 2018; 14(5):970-976. PubMed ID: 30197333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular heterogeneity of malignant pleural mesotheliomas].
    Tranchant R; Montagne F; Jaurand MC; Jean D
    Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].
    Multidisciplinary Committee of Oncology, Chinese Physicians Association
    Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
    J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.